Search results
Essential thrombocythemia (ET), or primary thrombocytosis, is a rare blood disorder in which your bone marrow makes too many platelets. Your bone marrow makes most of your body’s blood cells, including platelets. With essential thrombocythemia, blood cell production goes wrong, causing you to have abnormal and excess platelets.
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or microvascular vasospastic tendency. Symptoms and signs may include headache (ocular migraine), paresthesias, bleeding, erythromelalgia, or digital ischemia.
Essential thrombocythemia is considered a myeloproliferative neoplasm, in which certain blood-producing cells in the bone marrow reproduce excessively. The cause is a genetic mutation usually in the Janus kinase 2 (JAK2), calreticulin (CALR), or thrombopoietin receptor (MPL) genes.
- www.mayoclinic.org
- › …
- › Diseases & Conditions
Dec 30, 2022 · Your medical history, including recent infections, surgical procedures, bleeding and anemia. All medications, vitamins and other supplements you take, including doses. Questions to ask your doctor. Take a family member or friend along, if possible, to help you remember the information you're given.
Mar 28, 2024 · Essential thrombocythemia (ET) is a rare form of blood cancer that causes the bone marrow to produce too many platelets (the blood cells responsible for clotting). This excessive production can cause the inappropriate formation of blood clots that can block blood vessels, referred to as thrombosis .
Overview: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microcirculatory symptoms (e.g., headaches, lightheadedness, and acral paresthesias), and, les...
Jan 9, 2023 · INTRODUCTION. Essential thrombocythemia (ET) is one of the chronic myeloproliferative neoplasms (MPN), which are collectively characterized by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency.
